Physician Wealth Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Physician Wealth Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.33K	Sell	19 -2	-10%	-$209	﹤0.01%	1441
2026 Q1	$2.21K	Hold	21	–	–	﹤0.01%	1307
2025 Q4	$1.83K	Buy	21 +12	+133%	+$982	﹤0.01%	1328
2025 Q3	$598	Hold	9	–	–	﹤0.01%	1767
2025 Q2	$498	Buy	+9	New	+$432	﹤0.01%	1714

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Physician Wealth Advisors's PTGX Position: Q2 2026 in Review

Physician Wealth Advisors reduced its Protagonist Therapeutics (PTGX) stake by 9.5% in Q2 2026, selling an estimated $209 and leaving 19 shares worth $2.33K. The position accounts for ﹤0.01% of the portfolio, ranked #1441.

Physician Wealth Advisors first reported a position in PTGX in Q2 2025 and has held it in 5 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Physician Wealth Advisors held 19 shares of Protagonist Therapeutics worth $2.33K as of Q2 2026.
Physician Wealth Advisors sold 2 Protagonist Therapeutics shares in Q2 2026, an estimated $209.
Protagonist Therapeutics made up ﹤0.01% of Physician Wealth Advisors's portfolio in Q2 2026, its #1441 holding.
Physician Wealth Advisors first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 5 quarters since.
344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Physician Wealth Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.